Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
Amazon Web Services Expands Bedrock GenAI Service
April 23, 2024
Why Microsoft Stands Out As A Pre-Earnings Buy
April 23, 2024
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
GRTS Stock News and Mentions of Gritstone bio, Inc. Stocktwits
Updated: April 25, 2024 (13:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Gritstone bio Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Gritstone bio, Inc. (GRTS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Gritstone bio stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Gritstone bio, Inc. (GRTS)
April 24, 2024 (19:31) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS - Gritstone Bio ( NASDAQ:GRTS )
NEW YORK, April 24, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ( "Gritstone" or the "Company" ) GRTS. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
April 20, 2024 (16:15) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
NEW YORK, April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ( "Gritstone" or the "Company" ) ( NASDAQ: GRTS ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
April 16, 2024 (16:51) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS - Gritstone Bio ( NASDAQ:GRTS )
NEW YORK, April 16, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ( "Gritstone" or the "Company" ) GRTS. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
April 15, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of "Off-the-Shelf" Neoantigen Vaccine Platform ( SLATE ) - Gritstone Bio ( NASDAQ:GRTS )
-- Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens ( including KRAS ) enabled the development of a more potent, KRAS-specific vaccine candidate ( ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (18:56) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS - Gritstone Bio ( NASDAQ:GRTS )
NEW YORK, April 08, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ( "Gritstone" or the "Company" ) GRTS. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
April 8, 2024 (13:35) / "Zacks Commentary" (by Zacks Equity Research)
Down -63.39% in 4 Weeks, Here's Why Gritstone bio ( GRTS ) Looks Ripe for a Turnaround
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
In Article Trend: Somewhat-Bullish
April 4, 2024 (17:32) / "Zacks Commentary" (by Zacks Equity Research)
Gritstone ( GRTS ) Plummets 58% in a Week: Here's Why
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
In Article Trend: Neutral
April 2, 2024 (18:45) / "Benzinga" (by Avi Kapoor)
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher - Acorda Therapeutics ( NASDAQ:ACOR ) , Gritstone Bio ( NASDAQ:GRTS )
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down 1.07% to 39,142.53 while the NASDAQ fell 1.14% to 16,209.12. The S&P 500 also fell, dropping, 0.85% to 5,199.28. Energy shares jumped by 0.6% on Tuesday.
In Article Trend: Neutral
April 2, 2024 (16:06) / "Benzinga" (by Avi Kapoor)
Crude Oil Surges Over 1%; US Factory Orders Increase In February - Acorda Therapeutics ( NASDAQ:ACOR ) , Gritstone Bio ( NASDAQ:GRTS )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 while the NASDAQ fell 1.17% to 16,205.37. The S&P 500 also fell, dropping, 0.89% to 5,196.96. Energy shares jumped by 0.6% on Tuesday.
In Article Trend: Neutral
April 2, 2024 (13:58) / "Benzinga" (by Avi Kapoor)
Dow Dips Over 400 Points; Paychex Posts Downbeat Sales - Canoo ( NASDAQ:GOEV ) , Acorda Therapeutics ( NASDAQ:ACOR )
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 400 points on Tuesday. Following the market opening Tuesday, the Dow traded down 1.08% to 39,140.90 while the NASDAQ fell 1.49% to 16,152.79. The S&P 500 also fell, dropping, 0.99% to 5,191.80.
In Article Trend: Neutral
April 2, 2024 (12:04) / "Benzinga" (by Avi Kapoor)
Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - VirTra ( NASDAQ:VTSI )
Shares of VirTra, Inc. VTSI rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter results. VirTra posted GAAP earning of 25 cents per share, beating market estimates of 17 cents per share.
In Article Trend: Neutral
April 2, 2024 (11:14) / "Benzinga" (by Avi Kapoor)
Paychex, PVH And 3 Stocks To Watch Heading Into Tuesday - PVH ( NYSE:PVH ) , Paychex ( NASDAQ:PAYX )
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Paychex, Inc. PAYX to report quarterly earnings at $1.37 per share on revenue of $1.46 billion before the opening bell, according to data from ...
In Article Trend: Neutral
April 2, 2024 (03:00) / "GlobeNewswire" (by Inc)
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
EMERYVILLE, Calif., April 01, 2024 ( GLOBE NEWSWIRE ) -- Gritstone bio, Inc. ( Nasdaq: GRTS ) , a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (20:01) / "Benzinga" (by Globe Newswire)
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA ( ctDNA ) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer ( MSS-CRC ) - Gritstone Bio ( NASDAQ:GRTS )
-- Early progression-free survival ( PFS ) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ( [95% CI, 0.34-1.67]. 62% censored ) and 0.52 ( 48% relative risk reduction of progression or death with GRANITE vs. control ) in a high-risk group, where clinical data ...
In Article Trend: Neutral
March 18, 2024 (12:54) / "Zacks Commentary" (by Zacks Equity Research)
Do Options Traders Know Something About Gritstone bio ( GRTS ) Stock We Don't?
Investors need to pay close attention to Gritstone bio (GRTS) stock based on the movements in the options market lately.
In Article Trend: Neutral
March 5, 2024 (23:45) / "Zacks Commentary" (by Zacks Equity Research)
Gritstone bio Inc. ( GRTS ) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 27.78% and 116.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 5, 2024 (01:19) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
NEW YORK, March 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. ( "Gritstone" or the "Company" ) ( NASDAQ: GRTS ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 1, 2024 (17:08) / "Benzinga" (by Vandana Singh)
Why Is Gritstone Bio Stock Trading Lower? - Gritstone Bio ( NASDAQ:GRTS )
Gritstone bio Inc GRTS shares are trading lower after the company announced an approximately 40% reduction of its workforce.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website